Atlant Clinical to Conduct a Multicenter Clinical Trial in Patients with Peripheral Artery Disease (PAD)

Atlant Clinical announces winning a tender held by an international pharmaceutical company to conduct a multicenter Phase III clinical trial in vascular medicine. The study will be conducted in Russia, Belarus, Georgia, Ukraine and Kazakhstan.

The study will include more than 350 patients with peripheral arterial disease (PAD) at up to 30 sites, and will last for around one year. Atlant Clinical will be responsible for the whole spectrum of clinical and other services for the trial including biostatistics and data management, medical writing, and regulatory support.

In this study, PAD refers to artery disease in lower extremities. Narrowing or blockage of vessels that carry blood from the heart to the legs may lead to leg pain and severe health impairment. It is primarily caused by atherosclerosis, the buildup of fatty plaque in the arteries. According to recently published estimations, around 202 million people globally lived with PAD in 2010.

Around 70% of individuals with PAD lived in low/middle income regions of the world. Prevalence of PAD increased with age and the estimated number of individuals with PAD increased by 29% in low/middle income regions and by 13% in high-income regions from 2000 to 2010 due to population ageing (Fowkes et al., Nature Reviews Cardiology. 2017 (14): 156–170).

Chief executive officer of Atlant Clinical Michael Groubman said: “We are grateful to our Sponsor for placing its trust in Atlant Clinical. The project is strategically important for our company, as it is the third project from this Sponsor, highlighting its trust for Atlant and our professional capabilities. Cardiovascular diseases are among the major therapeutic areas in our portfolio, and we will be happy to apply our expertise to conduct the trial at the highest quality level. We have assigned an experienced and talented team with strong experience in the cardiovascular field to the project.

“We look forward to beginning the project and to continuing our collaboration with the Sponsor in bringing new and effective drugs to the market.”

More About This Company